Abstract Cognitive impairment (CI) is a serious complication of multiple sclerosis (MS), and the domains affected are well established, but new affected domains such as theory of mind are still being identified. The evidence that diseasemodifying therapies (DMTs) improve and prevent the development of CI in MS is not solid. Recent studies on the prevalence of CI in MS among people treated with DMT, although not as solid as studies completed prior to DMT introduction, suggest that CI remains a problem even among people on DMTs and that CI occurs frequently even at the very earliest stages of MS. Functional MRI studies and studies using diffusion tractography show that the impact of lesions on cognition depends on the particular cortical networks affected and their plasticity. Cognitive rehabilitation and Lamphetamine appear promising symptomatic treatments for CI in MS, while, cholinesterase inhibitors and memantine have failed, and data on Ginkgo and exercise are limited. We need more work to understand better CI in MS and develop treatments for this serious complication of MS.
Introduction
Cognitive Impairment (CI) is one of the most devastating complications of multiple sclerosis (MS). More than 30 reviews on the subject have been published in the last year. Particularly useful recent reviews include the work by Benedict et al. [1•] and Julian et al. [2•] . In this review, we will try to include new developments not covered in these previous reviews, with the objectives of determining the prevalence and incidence of CI in MS and, in particular, determining what the current rates are after the introduction of disease-modifying therapies (DMTs), determining what information we have on the impact of DMTs on CI, reviewing some novel developments in imaging correlates of CI, and reviewing pharmacological interventions not covered in previous reviews.
Affected Domains
The domains frequently impaired in people with MS are information-processing speed, working memory, verbal and visual memory, verbal fluency, and executive functions [3] . Two batteries have been validated and have gained widespread acceptance in the assessment of CI in MS: Rao's Brief Repeatable Battery (BRB) [3] and the Minimal Assessment of Cognitive Function in MS (MACFIMS) [4] . A recently identified impaired domain is theory of mind (ToM); ToM is the ability to deduce other people's thoughts on the basis of verbal and nonverbal cues. Similarly, empathy is the ability to deduce other people's emotions on the basis of verbal and nonverbal cues. Banati et al. recently found that ToM is another frequently impaired domain in MS [5] , and functional MRI (fMRI) studies suggest that reorganization of the cortical networks controlling ToM is responsible for the difficulties people with MS have in performing ToM tasks [6•] . After multiple studies, it is now well accepted that CI in MS has a pattern of impairment akin to subcortical diseases such as small vessel disease associated with aging; however, it is interesting that we are still identifying new impaired domains, such as ToM suggesting that there may be other frequently affected domains in people with MS that are yet to be identified.
Prevalence, Incidence, and Impact of CI in Untreated Populations
Prevalence rates of CI in MS of 40%-60%, derived from the studies by Rao [3] and Amato [7] , respectively, are frequently cited. Amato et al. followed a cohort of MS patients recruited prior to the introduction of a DMT for more than 10 years, providing us with an approximate estimate of incidence rate of CI. In the study by Amato et al., the frequency of CI increased from 26% at baseline to 56% at the follow-up assessment 10 years later [7] . Both the studies by Rao [3] and Amato [7] show that people with MS and CI are socially isolated and frequently unemployed. Morrow et al. followed a cohort of 97 employed subjects with MS for 41±18 months with detailed neuropsychological testing and current employment determinations. They found that both the Symbol Digit Modality Test (SDMT) and the total recall score from the California Verbal Learning Test-II (CVLTII-TR) accounted for the most variance in employment and that a decrease of 2.0 points on the CVLTII-TR raw score and/or of 4.0 on the SDMT raw score was associated with loss of employment [8•] . D'Orio et al. found, in a retrospective review of 81 patients with MS, that the occurrence of self-reported falls was increased with higher levels of impairment on verbal memory [9] . Taken together, this information indicates that without treatment, CI in people with MS becomes significantly more frequent and results in a decrease in independence and quality of life.
Effects of DMTs on Incidence of CI
The prevalence and incidence estimates derived from the studies by Rao [3] and Amato [7] predate the introduction of DMTs. Unfortunately, although DMTs have been available for more than 16 years, it is still unclear what the prevalence and incidence rates are in people with MS who have been on DMTs for most of the time since their diagnosis of MS and what impact the DMTs have in preventing the development of CI. Table 1 summarizes the reviewed information on DMTs and cognition.
Interferon B and Glatiramer Acetate
Glatiramer acetate (GA) and various formulations of interferon B have been the main DMTs for more than 10 years, and they have a well-established record of reducing relapses and being very safe. The phase III trial in relapsing-remitting MS of weekly intramuscular interferon B-1a included the most detailed neuropsychological assessment of the effect of a DMT in a randomized placebo-controlled trial, and it is a shame that other DMT trials that have followed have not made any effort to either match or improve on the methods of this landmark study. This phase III study evaluated in detail the cognitive performance in 166 subjects who participated in the trial. It showed significant differences between the treated and placebo groups of approximately 0.4 standard deviations (SDs)above the mean in the composite outcome and 1.2 SDs in the set of tests assessing visuospatial abilities and executive function [10] . Both the placebo and treated groups improved on their scores, although there was a larger improvement for the treated group and the difference in improvement was evident even at the 6-month evaluation. Although these results are a bit difficult to interpret because improvement was seen also in the placebo group, they suggest a beneficial effect from reduced inflammation after the start of the interferon that results in a better ability to improve on cognitive test performance, suggesting improved function of the cortical-subcortical networks responsible for learning and strategy generation. A second outcome from this study was the difference in progression of CI. The percent of patients with deterioration in their cognitive performance on the PASAT was 17% for interferon B-1a and 29% for placebo, but this difference was not statistically significant [10] . Seeing an effect on the progression of CI on the PASAT is difficult because the practice effect that results in improved performance on the test will counteract the effect of the disease itself. So we have class I evidence that treatment with intramuscular interferon B-1a results in a larger improvement in cognitive performance than does a placebo, but we have no solid evidence so far that intramuscular interferon B-1a alters the rate of progression of CI in people with MS. Improvement in delayed recall from year 2 to year 4 after randomization was seen in a small subset of 30 patients who participated in the original trial with interferon B-1b, but this study did not include cognitive evaluation at the start of the study [11] . In the North American trial of interferon B-1b for secondary progressive MS, interferon B-1b had no effect over a 3-year period of administration on the BRB [12] . Neuropsychological testing in the phase III trial with GA did not show significant differences between placebo and GA groups [13] . No data on cognition are available from the three times a week subcutaneous interferon B-1a trials or any of the more recent headto-head studies comparing interferon B and GA. It is unfortunate that, so far, so little data have been generated on the effect of these other DMTs on cognitive impairment in MS; the data with interferon B-1b supports the findings seen with the more robust study done with intramuscular interferon B-1a.
Natalizumab and Fingolimod
Natalizumab and Fingolimod are newer DMTs approved for MS. The phase III studies AFFIRM [14] and SENTINEL [15] with Natalizumab did not include cognitive assessment beyond the PASAT; in the AFFIRM study, 7% of patients on Natalizumab experienced sustained worsening performance on the PASAT versus 12% on placebo, which was statistically significant. In the SENTINEL study, no difference was seen on sustained worsening on the PASAT between subjects on weekly interferon-B-1a alone and those on the combination of interferon and Natalizumab [16•] . Uncontrolled studies have shown significant improvements in cognitive function after the start of Natalizumab, but these studies lacked adequate control groups [17] [18] [19] . Little is known about the effects on cognition of Fingolimod; although both phase III studies with this drug included the MS Functional Composite, none of them reported the changes on the PASAT component separately from the other two components of the composite score [20, 21] .
Together, the results of these limited placebo-controlled data with DMTs suggest that two different phenomena occur. First, there may be actual improvement in cognitive function that occurs following the start of some DMTs. This improvement is best documented in the case of intramuscular interferon B-1a, and it is most prominent in visuospatial tasks, attention, and executive functions and less robust in delayed recall tasks. Understanding what this improvement correlates to is difficult, since, after repeated testing, people, even those on placebo, show significant improvement as they learn how to execute the cognitive tests better. It is tempting to hypothesize that some of this improvement seen after the start of interferon B-1a and, possibly after starting interferon B-1b or Natalizumab, results from better function in the widely distributed neuronal networks that are responsible for practice effects. The improved function in these networks being due to a reduction in their exposure to an inflammatory milieu. This "improved practice" dominates analyses that focus on mean group performances with short-term follow-up. A second type of effect is captured by analyses that focus on sustained worsening on a particular test. This sustained progression is more difficult to capture than short-term improvement because it is not common, requires a longer period of follow-up to manifest, and is masked by practice effects but it is encouraging to see there was a trend on this type of outcome favoring intramuscular interferon B-1a versus placebo and a clear effect when Natalizumab was compared to placebo.
In the present authors' opinion, it is a major oversight that CI has been neglected as a relevant outcome in trials with DMTs and that, after more than 10 years following the introduction of interferon B and GA, we still cannot say for sure that they have any impact on the progression of CI in MS. It is reassuring to know that interferon B-1a has an effect on improvement in cognitive performance greater than what is seen with placebo, but it is not clear that this is a clinically meaningful outcome. 
Incidence and Prevalence of CI in Samples of Subjects With MS Treated With DMTs
Since we lack data from randomized placebo-controlled studies other than the interferon B-1a observational studies, the long-term open-label extension of the placebo-controlled studies could provide us with some idea of what the incidence and prevalence of CI are in people who are treated with DMT. This is a key piece of information needed for counseling patients with MS in current times. Data regarding CI in samples of subjects who have been on DMTs for most of their disease duration are scarce. The long-term follow-up study of the landmark phase III trial with GA assessed CI in 153 (67%) of the original 251 subjects 10 years after the start of the study. This study showed that worsening of more than 0.5 SDs on the composite neuropsychological score derived from BRB occurred in 19% of subjects over 10 years [22] . At the end of this study, 55% of subjects had measurable impairment, defined as a score worse than 2 SDs below the norm on a single test, or a score worse than 1 SD below the mean on two tests, consistent with the overall minimal change from baseline for scores where 50% of subjects were impaired [22] . These criteria for impairment are less stringent than the ones used by Amato et al. Although the follow-up study with GA is reassuring when compared with the results from Amato et al., 39% of subjects were lost to follow-up in the GA study. This fact can introduce significant bias and does not allow one to exclude a worse-case scenario where all of the subjects lost to follow-up could have developed CI. A longitudinal observational study documented the changes in cognitive function after 3 years of starting treatment with either low-or high-dose interferon beta 1a three times a week (Rebif®) (44 mcg, n 0236; 22 mcg, n 0223) at physician's discretion, follow-up was available for 318 (69%) of the initial subjects. Baseline impairment was similar in both groups (44 mcg, 15%; 22 mcg, 23.2%), and the proportion of cognitively impaired subjects increased by 1.3% in the low-dose group and remained stable in the high-dose group (hazard ratio, 0.68; 95% confidence interval, 0.480-0.972), suggesting a small but significant protective effect from the higher dose of interferon [23] . Other studies we found in our review (Duque et al. [24] , Brooks et al. [25] , Baumstarck-Barrau et al. [26] ., Brissart et al. [27] , and Glanz et al. [28] ) did not report the frequency of DMT use.
The data we found from either observational studies or extension of placebo-controlled studies are insufficient to give any meaningful answer to the question of current patients with MS as to whether they can still expect a greater than 50% chance of developing CI after 10 years now that we have DMTs available.
Prevalence of CI in Clinically Isolated Syndrome and Radiologically Isolated Syndrome (RIS)
DMT nowadays are frequently started after the first symptoms occur without waiting until a second attack has occurred. People who have had only one attack suggestive of MS are said to have clinically isolated syndrome (CIS). People with CIS are considered to be in the earliest stage of MS. Unfortunately, even at this early stage, cognitive deficits are frequently present. Feuillet et al. found CI in 57% (n040) of subjects with CIS 3 months after diagnosis (0.5SD). The pattern of test results showing impairment was similar to that for the tests frequently impaired in subjects with longstanding MS [29] . Kocer found that subclinical dysfunction, defined as impairment on at least one test from their battery, was present in 80% of the CIS group and none of the controls [30] . Feinstein et al. found significant decline in visuospatial memory among 48 patients with CIS followed over 4.5 years [31] . Reuter et al. showed rapid development of cognitive impairment in 24 subjects who were followed over 5 years after CIS diagnosis, where 29% were impaired at baseline and 54% were impaired after 5 years [32] . These data indicate that individuals at the earliest stage of MS often present with CI and highlight the importance of cognitive testing at the time of the first demyelinating attack both for counseling regarding vocational assessment and coping strategies and to monitor the progression of MS.
The term radiollogically isolated syndrome (RIS) refers to people with no symptoms or abnormalities on a physical exam who have lesions typical for MS on MRI. Although very controversial, it is becoming accepted that some of these people have an even earlier stage of MS than CIS. In this situation, detailed cognitive testing, as shown by the recent studies by Lebrun [33•] and Amato [34•] , is very useful, since the pattern and frequency of impairment was comparable between RIS subjects and subjects with MS [33•] and a significant proportion of people with RIS (28%) fit impairment criteria [34•] . If people with RIS show signs of CI, they should not be labeled as RIS, and it follows that the definition of RIS needs to be modified to people with "no signs, symptoms, or abnormalities on physical and/ or cognitive exams." This way, there is a clear difference between RIS and CIS, making the diagnostic step from RIS to CIS indicative of progressing impairment. Whether the occurrence of CI in subjects with RIS predicts the occurrence of future attacks is an important unanswered question. , using diffusion tensor imaging tractography, suggests that part of the lesion load paradox can be because damage to a single WM tract can affect different cognitive domains and a single cognitive domain may be affected after damage of several different WM tracts. In their study with 82 subjects with MS they were able to classify correctly 76.8% of the subjects as either cognitively impaired or not, using a novel statistical technique, the random forest strategy. Severity of fiber damage as measured by DTI in lesions in the cingulum, superior cerebellar peduncles, and uncinate fasciculus were the main MRI variables driving the classification strategy [35•] .
Interesting new developments using fMRI have highlighted an imbalance in people with MS in the function of two opposing cortical networks: the default network that is active at rest and the control network that is engaged during most cognitive tasks. Hawellek et al. examined the relationship between these two networks and CI in 16 subjects with MS. They found that subjects with MS with higher CI have higher connectivity in the default mode network and decreased activity in the control network. Hawellek et al. point out the fact that similar findings are seen in normal aging and that this finding in MS suggests that gradual but incomplete decline in the function of white matter connections and the plastic response of the brain to this decline underlies CI in MS. According to Hawellek et al. as the brain adapts to decline in white matter connections, it makes cognitive representations such as receptive fields less specific and more broadly tuned and because of this people with MS may have difficulties switching off their default network and turning on their control network to engage the necessary cognitive resources to sustain attention to the tasks and process information rapidly and effectively [36•] .
Symptomatic Treatments
Since DMTs may not alter the CI course completely and since CI may be already present at the time of diagnosis, we still need treatments that improve cognitive performance even if they do not prevent the development of CI. There has been some slow progress in this area, but much more work is still needed. Table 2 summarizes the results of our review of the literature.
Cognitive Rehabilitation
It may be possible to improve cognitive performance by learning strategies for using available cognitive resources more efficiently or by doing repeated cognitive exercises that may result in a training effect. The fact that people on placebo have significant improvement in their scores on cognitive tests indicates that such practice effects really occur and that "cognitive exercise" could result in some degree of improvement similar to what physical exercise can do for improving strength.
Studies assessing the effects of "cognitive exercise" are starting to appear. A smaller study comparing subjects assigned to a 6-week cognitive intervention using the RehaCom software (n011), placebo (n014), or no treatment (n015) found significant improvements in executive functioning and verbal learning after 6 weeks of training. The verbal-learning effect was sustained up to a year [37] . Chiaravalloti et al. studied the approach of teaching a specific cognitive strategy, showing that training in the story memory technique did not improve verbal learning in subjects assigned to treatment (n014) versus those assigned to placebo (n015), but a subgroup analysis showed significantly improved verbal learning in the subgroup with verbal-learning impairment at baseline [38] . Stuifbergen et al. [39•] recently reported a randomized trial comparing a comprehensive computerized cognitive rehabilitation strategy with waiting list control. They found that the rehabilitation strategy resulted in improved verbal learning, increased frequency of use of compensatory strategies, and improved family member reports of the subject's cognitive function.
These early studies suggest that cognitive rehabilitation approaches can work. Much more work is needed to find the optimal therapy and determine the optimal length and intensity of administration. Further work is needed to understand how cognitive rehabilitation employs inherent neuroplasticity in a therapeutic context and whether there are ways to enhance this effect.
Stimulants
Stimulants are, by definition, a class of drugs that yield a net increase in physical or cognitive performance. Most stimulants work by increasing the metabolism and intercellular concentrations of dopamine. The effects of stimulants have been tested on various facets of concentration and memory in healthy people, where they are known to improve various aspects of cognitive function; thus, the hypothesis that would have similar effects in people with CI from MS seems logical.
Harel et al. compared the difference in performance on the PASAT between subjects randomized to either a single dose of methyphenidate or placebo. Treatment with methylphenidate resulted in a significantly higher improvement on the PASAT than did treatment with placebo [40] . Amphetamine is known to improve attention in ADHD, and the L-enantiomer of amphetamine may have fewer side effects than d-amphetamine. Benedict et al. [41] examined three doses (15, 30 , and 45 mg) of the L-amphetamine and placebo for their effects on processing speed and memory in subjects with MS demonstrating CI. Benedict et al. used a cross-over design where subjects were assigned to four possible ascending sequences of single doses of 15, 30, or 45 mg of L-amphetamine with placebo included after one of the amphetamine doses. The subject's performance on a neuropsychological test battery was assessed 2 h after the dose to exploit peak serum levels of the study drug. After a washout period of 1 week, the next ascending dose and its subsequent testing session were administered. L-amphetamine had no significant effect on episodic memory, while processing speed and working memory improved significantly as measured by the PASAT, SDMT, and part A of the trail-making test with the 30-and 45-mg doses [41] . The same group evaluated the efficacy of L-amphetamine in a randomized, placebocontrolled, double-blind parallel group trial including 151 subjects from 33 MS clinics across the U.S. treated for a period of 29 days. The score on the Subject Global Assessment of Change (SGAC) and the Symbol Digit Modalities Test (SDMT) were the primary outcome measures. The secondary outcomes were performance on the following tests: California Verbal Learning Test-II (CVLTII), BVMTR (Brief Visual Memory Test-Revised), and PASAT. To be eligible for the study, patients had to score worse than 1.5 SD below the mean on the SDMT or worse than 1 SD below the mean on the CVLTII Delayed Recall (CVLTII-DR) or (PASAT). Lamphetamine (30 mg) significantly improved the CVLTII-DR (p 0.01), BVMTR-DR (p < .01), and BVMTR-TL (p0.04) scores, but not the scores on the primary outcomes [42] . A subgroup analysis of these data showed that most of the improvement in memory function occurred among subjects with baseline memory impairment [42] . Modafinil is a stimulant that differs from amphetamine and methylphenidate in its mechanism of action, since it does not work at the level of dopamine reuptake. In an open-label trial with treatment masked from evaluators, Wliken et al. found that the group randomized to treatment with modafinil plus interferon B-1a (n023) performed significantly better than the group randomized to only interferon B-1a on several attention measures (Auditory Consonant Trigrams, Digit Span and Letter-Number Sequencing Subtest) and on the Lexical Fluency Task WAIS-III [46] . A more recent, larger, randomized placebo-controlled trial of modafinil for fatigue [47•] with 121 subjects failed to show a significant improvement for fatigue; however, the treated group had statistically significant higher improvement on the SDMT than did the placebo group, while the reverse occurred on the PASAT [47•] .
While the results with methyl-phenidate and L-amphetamine are promising, the results of the trial of L-amphetamine need to be replicated in a study that has verbal and nonverbal memory as its primary outcome, and the results with methyl-phenidate need to be assessed over a longer follow-up period.
Cholinesterase Inhibitors
Acetylcholine is a neurotransmitter that facilitates memory and information processing. Several studies have indicated that decreased levels of acetylcholine in the brain are associated with an increase of CI in several neurodegenerative diseases, including Alzheimer's disease (AD) and Lewy body dementia, and there is some evidence that there is a cholinergic deficit in patients with MS and that this could underlie some of the CI in MS. Thus, it is logical to think that cholinesterase inhibitors could improve cognitive function in MS. In a small sample of subjects, a single dose of Rivastigmine (n016) was compared with placebo (n016) and resulted in faster processing speed in a modified version of the PASAT test that can be administered while the subject is in the MRI scanner. In this study, MS patients had wider prefrontal activation on fMRI than did matched healthy controls. The subjects with MS that were randomized to receive a single dose of Rivastigmine showed greater improvement in their processing speed, as compared with the placebo group of MS subjects. After receiving Rivastigmine, the subjects with MS showed an activation pattern on functional MRI similar to that of healthy controls, while the subjects with MS who received placebo still had wide prefrontal activation [43] . Treatment with Donepezil, another cholinesterase inhibitor, at 10 mg a day for 24 weeks, had a positive effect on verbal learning, as measured with the Selective Reminding Test (SRT), in a small pilot study with 69 subjects with MS who scored 0.5 SD or more below the mean on the Rey Auditory Verbal Learning Test [44] . Unfortunately, these results were not replicated in a larger multicenter trial following the same paradigm [45] . Thus, so far the results from clinical trials with cholinesterase inhibitors have been mixed, with positive effects seen in small trials that were not replicated in a large, adequately powered placebo-controlled trial, and thus, at this time, there is insufficient evidence to recommend their use. However, it is still possible that cholinesterase inhibitors have a beneficial effect in a subset of patients with CI and on a cognitive outcome that has not been studied, so clinical research with them should not be abandoned.
Memantine
Excessive activation of the NMDA glutamate receptor is known to occur in AD, and it is thought to be responsible for neuronal dysfunction responsible for a portion of the cognitive impairment that occurs in AD. There is evidence in MS of excessive glutamate concentration, as well as abnormal expression of the transporters responsible for its reuptake. Memantine is a use-dependent NMDA receptor that does not have the side effects of nonselective NMDA antagonists but is still able to antagonize NMDA in situations where there is excessive glutamate release. Memantine is effective at improving cognition in patients with severe AD, and since glutamate is elevated in MS, it seemed plausible that Memantine could be effective at improving CI in MS. Villoslada et al. had to suspend early their study of Memantine for CI in MS because of intolerable side effects [48] . Our group conducted a randomized placebo-controlled multicenter trial comparing treatment with memantine (n0 54) versus placebo (n060) in subjects with MS who performed worse than 0.5 SD below the mean on the PASAT or the CVLTII. In our study, we used a slow titration phase, and this resulted in lower discontinuation rates when compared with Villoslada et al., but our subjects treated with memantine still had a higher frequency of adverse events than did the placebo group-particularly, vague neurological complaints. In our group's study, we saw no improvement in any of the cognitive tests in the battery, which included the PASAT, CVLTII, Stroop, SDMT, COWAT, and DKEFS [49•] . Thus, memantine does not appear to be effective for CI in MS and it is poorly tolerated.
Ginkgo Biloba
Ginkgo biloba has unique compounds that antagonize the platelet activating factor (PAF). PAF is both a neurotransmitter and an inflammatory mediator and is known to be elevated in MS. PAF works in glutaminergic synapses by serving as a retrograde transmitter that enhances the release of glutamate on the presynaptic terminal after repeated activation of the synapse. There have been several trials in AD studying the effects of Ginkgo biloba extract, with the earlier trials suggesting a beneficial effect that was not reproduced in more modern trials. Since there is inflammation in MS and excessive glutamate release, we hypothesized that treatment with Ginkgo biloba extract could improve cognitive performance in people with MS. We conducted a pilot randomized placebo-controlled trial with Ginkgo biloba 120 mg twice a day for 3 months, where we found that subjects with MS treated with Ginkgo (n020) improved significantly more on the Stroop test than did subjects treated with placebo (n018) [50] ; the results of our larger randomized, placebo-controlled multicenter trial with 110 subjects were presented at the 2011 American Academy of Neurology annual meeting and are in press in Neurology. The trial results were essentially negative, with no effect seen in any of the cognitive outcomes [51] .
Yoga and Excercise
Daily physical activity has been shown to have protective effects in patients with other neurological conditions. Studies of effects of physical exercise on cognition in people with MS so far are limited. In a cross-sectional study using the data from a pilot study assessing a rehabilitation intervention, Motl et al. showed that there was a positive correlation between amount of daily physical exercise and processing speed, but not learning and memory [52] . Yoga and aerobic exercise were evaluated in subjects with MS (n069) in an RPCT study where subjects were randomized to yoga, exercise, or a waiting list control in combination with their regular MS DMTs. Neither active treatment showed evidence of improvement in measures of attention or alertness, but both active interventions improved fatigue [53] ; this study did not include some yoga poses traditionally thought to improve attention and concentration. such as: "flying bird," "standing or sitting forward bend," "star," "child," "salaam," "hare," "cat/cow" combination pose, "savasana" corpse, "crocodile," "cobra/sphinx" combination, "supine knee squeeze," and "warrior/eagle" combinations. Further research should be done on the efficacy of a combined physical and cognitive rehabilitation program including yoga and mindfulness meditation in the battery.
Conclusion and Future Directions
CI is a serious complication of MS. Intramuscular interferon B-1a improves cognitive function over the short term more than does placebo, and Natalizumab significantly reduces the development of sustained worsening on the PASAT. The longterm effects of DMTs on cognition are uncertain. Although we hope that earlier diagnosis and treatment of MS prevents the development of CI, it appears that some degree of CI is present in many people with MS immediately after their initial symptoms and may be present even before symptoms develop. The pattern of cognitive dysfunction is well established, but recently, difficulties with theory of mind have been added to the domains frequently impaired in MS. Imaging studies continue to find interesting correlates of CI in MS, and recent studies assessing functional connectivity show that CI in MS shares an underlying pathophysiology with other processes that affect cognition, such as aging. Pharmacologic as well as complementary and alternative symptomatic treatments for CI remain limited, with L-amphetamine being the most promising. Cognitive rehabilitation strategies, as well as physical exercise interventions, are also showing promising results. Future studies should attempt to combine information from MRI and cognitive testing to select the best pharmacologic intervention and also look at combinations of stimulants and cognitive rehabilitation. Well-designed studies to determine the impact of DMTs on cognition are greatly needed, and it is unfortunate that phase III studies of new DMTs have neglected cognition as part of their secondary outcomes. Well-designed long-term longitudinal observational studies are also needed, but strategies to prevent loss at follow-up are critical to ensuring that their results are useful.
